Transplantation-associated thrombotic microangiopathy (TA-TMA) is a devastating consequence of allogeneic haematopoietic stem cell transplantation (HSCT) with a mortality rate of 60--90%. None of the interventions used, as used up till now in idiopathic thrombotic thrombocytopaenic purpura (TTP) (fresh frozen plasma transfusion, plasma exchange and steroids), were effective to treat TA-TMA \[[@ref1]\]. We report a dramatic improvement of TA-TMA in two HSCT patients \[conditioning, cyclophosphamide, total body irradiation, graft-*versus*-host disease (GVHD) prophylaxis\] using doxycycline.

A 36-year-old woman with Hodgkin\'s lymphoma received an allogeneic HSCT in December 2002. Twelve months later, she developed a biopsy-proven TMA (proteinuria, 3 g/day, microscopic haematuria, oliguric acute renal failure with creatinine level at 680 µmol/L; haemoglobin Hb, 6.3 g/dL; schistocytes; platelet count, 35 × 10^9^/L; LDH, 1754 IU/L). The serum complement proteins were at normal levels, no mutations of the membrane cofactor protein were found and a plasma ADAMTS13 activity was found at 40%. Steroids, plasma exchange, fresh frozen plasma transfusion, vincristine and haemodialysis were tried with a partial response (haemoglobin, 7.3 g/dL, platelet 70 000/mm^3^ both after treatment). Doxycycline 200 mg daily was added for a suspected gastrointestinal *Bartonella* infection. Within two months, haemoglobin and platelet count rose without transfusion to 10.8 g/dL and 234 000/mm^3^, respectively. Despite improvement of haematological parameters, the patient remained dialysis-dependent. The second patient had a similar haematologic disease and course under doxycycline prescribed for a bartholinitis.

Five patients with TTP and *Bartonella*-like erythrocyte inclusions, successfully treated with doxycycline, experienced recurrence of their TTP following cessation of treatment \[[@ref3]\]. TA-TMA has a multi-factorial aetiology of endothelial damage. Doxycycline targeting the adherens junction on endothelial cells prevents vascular hyperpermeability \[[@ref4]\]. Doxycycline as a potential treatment of TA-TMA warrants further studies.
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